Cargando…

Antitumor Reactive T-Cell Responses Are Enhanced In Vivo by DAMP Prothymosin Alpha and Its C-Terminal Decapeptide

Prothymosin α (proTα) and its C-terminal decapeptide proTα(100–109) were shown to pleiotropically enhance innate and adaptive immune responses. Their activities have been broadly studied in vitro, focusing primarily on the restoration of the deficient immunoreactivity of cancer patients’ leukocytes....

Descripción completa

Detalles Bibliográficos
Autores principales: Birmpilis, Anastasios I., Karachaliou, Chrysoula-Evangelia, Samara, Pinelopi, Ioannou, Kyriaki, Selemenakis, Platon, Kostopoulos, Ioannis V., Kavrochorianou, Nadia, Kalbacher, Hubert, Livaniou, Evangelia, Haralambous, Sylva, Kotsinas, Athanasios, Farzaneh, Farzin, Trougakos, Ioannis P., Voelter, Wolfgang, Dimopoulos, Meletios-Athanasios, Bamias, Aristotelis, Tsitsilonis, Ourania
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896021/
https://www.ncbi.nlm.nih.gov/pubmed/31717548
http://dx.doi.org/10.3390/cancers11111764
_version_ 1783476687666675712
author Birmpilis, Anastasios I.
Karachaliou, Chrysoula-Evangelia
Samara, Pinelopi
Ioannou, Kyriaki
Selemenakis, Platon
Kostopoulos, Ioannis V.
Kavrochorianou, Nadia
Kalbacher, Hubert
Livaniou, Evangelia
Haralambous, Sylva
Kotsinas, Athanasios
Farzaneh, Farzin
Trougakos, Ioannis P.
Voelter, Wolfgang
Dimopoulos, Meletios-Athanasios
Bamias, Aristotelis
Tsitsilonis, Ourania
author_facet Birmpilis, Anastasios I.
Karachaliou, Chrysoula-Evangelia
Samara, Pinelopi
Ioannou, Kyriaki
Selemenakis, Platon
Kostopoulos, Ioannis V.
Kavrochorianou, Nadia
Kalbacher, Hubert
Livaniou, Evangelia
Haralambous, Sylva
Kotsinas, Athanasios
Farzaneh, Farzin
Trougakos, Ioannis P.
Voelter, Wolfgang
Dimopoulos, Meletios-Athanasios
Bamias, Aristotelis
Tsitsilonis, Ourania
author_sort Birmpilis, Anastasios I.
collection PubMed
description Prothymosin α (proTα) and its C-terminal decapeptide proTα(100–109) were shown to pleiotropically enhance innate and adaptive immune responses. Their activities have been broadly studied in vitro, focusing primarily on the restoration of the deficient immunoreactivity of cancer patients’ leukocytes. Previously, we showed that proTα and proTα(100–109) act as danger-associated molecular patterns (DAMPs), ligate Toll-like receptor-4, signal through TRIF- and MyD88-dependent pathways, promote the maturation of dendritic cells and elicit T-helper type 1 (Th1) immune responses in vitro, leading to the optimal priming of tumor antigen-reactive T-cell functions. Herein, we assessed their activity in a preclinical melanoma model. Immunocompetent mice bearing B16.F1 tumors were treated with two cycles of proTα or proTα(100–109) together with a B16.F1-derived peptide vaccine. Coadministration of proTα or proTα(100–109) and the peptide vaccine suppressed melanoma-cell proliferation, as evidenced by reduced tumor-growth rates. Higher melanoma infiltration by CD3+ T cells was observed, whereas ex vivo analysis of mouse total spleen cells verified the in vivo induction of melanoma-reactive cytotoxic responses. Additionally, increased levels of proinflammatory and Th1-type cytokines were detected in mouse serum. We propose that, in the presence of tumor antigens, DAMPs proTα and proTα(100–109) induce Th1-biased immune responses in vivo. Their adjuvant ability to orchestrate antitumor immunoreactivities can eventually be exploited therapeutically in humans.
format Online
Article
Text
id pubmed-6896021
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68960212019-12-24 Antitumor Reactive T-Cell Responses Are Enhanced In Vivo by DAMP Prothymosin Alpha and Its C-Terminal Decapeptide Birmpilis, Anastasios I. Karachaliou, Chrysoula-Evangelia Samara, Pinelopi Ioannou, Kyriaki Selemenakis, Platon Kostopoulos, Ioannis V. Kavrochorianou, Nadia Kalbacher, Hubert Livaniou, Evangelia Haralambous, Sylva Kotsinas, Athanasios Farzaneh, Farzin Trougakos, Ioannis P. Voelter, Wolfgang Dimopoulos, Meletios-Athanasios Bamias, Aristotelis Tsitsilonis, Ourania Cancers (Basel) Article Prothymosin α (proTα) and its C-terminal decapeptide proTα(100–109) were shown to pleiotropically enhance innate and adaptive immune responses. Their activities have been broadly studied in vitro, focusing primarily on the restoration of the deficient immunoreactivity of cancer patients’ leukocytes. Previously, we showed that proTα and proTα(100–109) act as danger-associated molecular patterns (DAMPs), ligate Toll-like receptor-4, signal through TRIF- and MyD88-dependent pathways, promote the maturation of dendritic cells and elicit T-helper type 1 (Th1) immune responses in vitro, leading to the optimal priming of tumor antigen-reactive T-cell functions. Herein, we assessed their activity in a preclinical melanoma model. Immunocompetent mice bearing B16.F1 tumors were treated with two cycles of proTα or proTα(100–109) together with a B16.F1-derived peptide vaccine. Coadministration of proTα or proTα(100–109) and the peptide vaccine suppressed melanoma-cell proliferation, as evidenced by reduced tumor-growth rates. Higher melanoma infiltration by CD3+ T cells was observed, whereas ex vivo analysis of mouse total spleen cells verified the in vivo induction of melanoma-reactive cytotoxic responses. Additionally, increased levels of proinflammatory and Th1-type cytokines were detected in mouse serum. We propose that, in the presence of tumor antigens, DAMPs proTα and proTα(100–109) induce Th1-biased immune responses in vivo. Their adjuvant ability to orchestrate antitumor immunoreactivities can eventually be exploited therapeutically in humans. MDPI 2019-11-09 /pmc/articles/PMC6896021/ /pubmed/31717548 http://dx.doi.org/10.3390/cancers11111764 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Birmpilis, Anastasios I.
Karachaliou, Chrysoula-Evangelia
Samara, Pinelopi
Ioannou, Kyriaki
Selemenakis, Platon
Kostopoulos, Ioannis V.
Kavrochorianou, Nadia
Kalbacher, Hubert
Livaniou, Evangelia
Haralambous, Sylva
Kotsinas, Athanasios
Farzaneh, Farzin
Trougakos, Ioannis P.
Voelter, Wolfgang
Dimopoulos, Meletios-Athanasios
Bamias, Aristotelis
Tsitsilonis, Ourania
Antitumor Reactive T-Cell Responses Are Enhanced In Vivo by DAMP Prothymosin Alpha and Its C-Terminal Decapeptide
title Antitumor Reactive T-Cell Responses Are Enhanced In Vivo by DAMP Prothymosin Alpha and Its C-Terminal Decapeptide
title_full Antitumor Reactive T-Cell Responses Are Enhanced In Vivo by DAMP Prothymosin Alpha and Its C-Terminal Decapeptide
title_fullStr Antitumor Reactive T-Cell Responses Are Enhanced In Vivo by DAMP Prothymosin Alpha and Its C-Terminal Decapeptide
title_full_unstemmed Antitumor Reactive T-Cell Responses Are Enhanced In Vivo by DAMP Prothymosin Alpha and Its C-Terminal Decapeptide
title_short Antitumor Reactive T-Cell Responses Are Enhanced In Vivo by DAMP Prothymosin Alpha and Its C-Terminal Decapeptide
title_sort antitumor reactive t-cell responses are enhanced in vivo by damp prothymosin alpha and its c-terminal decapeptide
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896021/
https://www.ncbi.nlm.nih.gov/pubmed/31717548
http://dx.doi.org/10.3390/cancers11111764
work_keys_str_mv AT birmpilisanastasiosi antitumorreactivetcellresponsesareenhancedinvivobydampprothymosinalphaanditscterminaldecapeptide
AT karachaliouchrysoulaevangelia antitumorreactivetcellresponsesareenhancedinvivobydampprothymosinalphaanditscterminaldecapeptide
AT samarapinelopi antitumorreactivetcellresponsesareenhancedinvivobydampprothymosinalphaanditscterminaldecapeptide
AT ioannoukyriaki antitumorreactivetcellresponsesareenhancedinvivobydampprothymosinalphaanditscterminaldecapeptide
AT selemenakisplaton antitumorreactivetcellresponsesareenhancedinvivobydampprothymosinalphaanditscterminaldecapeptide
AT kostopoulosioannisv antitumorreactivetcellresponsesareenhancedinvivobydampprothymosinalphaanditscterminaldecapeptide
AT kavrochorianounadia antitumorreactivetcellresponsesareenhancedinvivobydampprothymosinalphaanditscterminaldecapeptide
AT kalbacherhubert antitumorreactivetcellresponsesareenhancedinvivobydampprothymosinalphaanditscterminaldecapeptide
AT livaniouevangelia antitumorreactivetcellresponsesareenhancedinvivobydampprothymosinalphaanditscterminaldecapeptide
AT haralamboussylva antitumorreactivetcellresponsesareenhancedinvivobydampprothymosinalphaanditscterminaldecapeptide
AT kotsinasathanasios antitumorreactivetcellresponsesareenhancedinvivobydampprothymosinalphaanditscterminaldecapeptide
AT farzanehfarzin antitumorreactivetcellresponsesareenhancedinvivobydampprothymosinalphaanditscterminaldecapeptide
AT trougakosioannisp antitumorreactivetcellresponsesareenhancedinvivobydampprothymosinalphaanditscterminaldecapeptide
AT voelterwolfgang antitumorreactivetcellresponsesareenhancedinvivobydampprothymosinalphaanditscterminaldecapeptide
AT dimopoulosmeletiosathanasios antitumorreactivetcellresponsesareenhancedinvivobydampprothymosinalphaanditscterminaldecapeptide
AT bamiasaristotelis antitumorreactivetcellresponsesareenhancedinvivobydampprothymosinalphaanditscterminaldecapeptide
AT tsitsilonisourania antitumorreactivetcellresponsesareenhancedinvivobydampprothymosinalphaanditscterminaldecapeptide